Assessment of Health Economics in Alzheimer's Disease (AHEAD): Treatment with Galantamine in Sweden

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.20, Iss.9, 2002-09, pp. : 629-637

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Galantamine vs Donepezil in the Treatment of Alzheimer's Disease

By Goldlist B. Gordon M. Naglie G.

Drugs & Aging, Vol. 20, Iss. 15, 2003-01 ,pp. : 1139-1140

Adis International

Access to resources Recommend Favorite

Assessing the Health and Economic Impact of Galantamine Treatment in Patients with Alzheimers Disease in the Health Care Systems of Different Countries

By Jaime Caro Maribel Salas

Drugs & Aging, Vol. 21, Iss. 10, 2004-01 ,pp. : 677-686

Adis International

Access to resources Recommend Favorite

Galantamine for Alzheimer's disease

By Prvulovic David Hampel Harald Pantel Johannes

Expert Opinion on Drug Metabolism and Toxicology, Vol. 6, Iss. 3, 2010-03 ,pp. : 345-354

Informa Healthcare

Access to resources Recommend Favorite

A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimers Disease

By Wilcock G.

Drugs & Aging, Vol. 20, Iss. 10, 2003-01 ,pp. : 777-789

Adis International

Access to resources Recommend Favorite

Current status and new developments with galantamine in the treatment of Alzheimer’s disease

By Tariot Pierre

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 12, 2001-12 ,pp. : 2027-2049

Informa Healthcare

Access to resources Recommend Favorite